Literature DB >> 19351262

Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission.

Silvia de Sanjose1, Georgina Mbisa, Susana Perez-Alvarez, Yolanda Benavente, Sukhon Sukvirach, Nguyen Trong Hieu, Hai-Rim Shin, Pham Thi Hoang Anh, Jaiyeola Thomas, Eduardo Lazcano, Elena Matos, Rolando Herrero, Nubia Muñoz, Monica Molano, Silvia Franceschi, Denise Whitby.   

Abstract

BACKGROUND: The aim of the present study was to estimate the prevalence of Kaposi sarcoma-associated herpesvirus (KSHV) in the female general population, to define geographic variation in and heterosexual transmission of the virus.
METHODS: The study included 10,963 women from 9 countries for whom information on sociodemographic characteristics and reproductive, sexual, and smoking behaviors were available. Antibodies against KSHV that encoded lytic antigen K8.1 and latent antigen ORF73 were determined.
RESULTS: The range of prevalence of KSHV (defined as detection of any antigen) was 3.81%-46.02%, with significant geographic variation noted. In Nigeria, the prevalence was 46.02%; in Colombia, 13.32%; in Costa Rica, 9.81%; in Argentina, 6.40%; in Ho Chi Minh City, Vietnam, 15.50%; in Hanoi, Vietnam, 11.26%; in Songkla, Thailand, 10%; in Lampang, Thailand, 8.63%; in Korea, 4.93%; and in Spain, 3.65%. The prevalence of KSHV slightly increased with increasing age among subjects in geographic areas where the prevalence of KSHV was high, such as Nigeria and Colombia, and it significantly decreased with increases in the educational level attained by subjects in those areas. KSHV was not statistically associated with age at first sexual intercourse, number of sex partners, number of children, patterns of oral contraceptive use, presence of cervical human papillomavirus DNA, or smoking status.
CONCLUSIONS: The study provides comparable estimates of KSHV prevalence in diverse cultural settings across 4 continents and provides evidence that sexual transmission of KSHV is not a major source of infection in the general population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351262     DOI: 10.1086/598523

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

1.  Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.

Authors:  Mahboobeh Safaeian; Koen Quint; Mark Schiffman; Ana Cecilia Rodriguez; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Raphael P Viscidi; Wim Quint; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2010-11-23       Impact factor: 13.506

Review 2.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

Review 3.  HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis.

Authors:  Eliane Rohner; Natascha Wyss; Zina Heg; Zully Faralli; Sam M Mbulaiteye; Urban Novak; Marcel Zwahlen; Matthias Egger; Julia Bohlius
Journal:  Int J Cancer       Date:  2015-07-28       Impact factor: 7.396

4.  Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections.

Authors:  Sang-Hoon Sin; Anthony B Eason; Rachele Bigi; Yongbaek Kim; SunAh Kang; Kelly Tan; Tischan A Seltzer; Raman Venkataramanan; Hyowon An; Dirk P Dittmer
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

5.  Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon.

Authors:  Kristen Stolka; Paul Ndom; Jennifer Hemingway-Foday; Jeniffer Iriondo-Perez; Wendell Miley; Nazzarena Labo; Jennifer Stella; Mahamat Abassora; Godfrey Woelk; Robin Ryder; Denise Whitby; Jennifer S Smith
Journal:  Cancer Epidemiol       Date:  2014-03-13       Impact factor: 2.984

6.  Prevalence of human herpesvirus 8 and hepatitis C virus in a rural community with a high risk for blood-borne infections in central China.

Authors:  T Zhang; N He; Y Ding; K Crabtree; V Minhas; C Wood
Journal:  Clin Microbiol Infect       Date:  2011-03       Impact factor: 8.067

7.  High seroprevalence of human herpesvirus type 8 infection in males with advanced lung carcinoma.

Authors:  Cheng-Chuan Su; Chun-Liang Lai; Shih-Ming Tsao; Ming-Nan Lin; Tang-Yuan Chu
Journal:  Med Microbiol Immunol       Date:  2014-08-15       Impact factor: 3.402

8.  Kaposi Sarcoma-Associated Herpesvirus in a Rural Ugandan Cohort, 1992-2008.

Authors:  Robert Newton; Nazzarena Labo; Katie Wakeham; Wendell Miley; Gershim Asiki; W Thomas Johnston; Denise Whitby
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

Review 9.  Kaposi sarcoma.

Authors:  Ethel Cesarman; Blossom Damania; Susan E Krown; Jeffrey Martin; Mark Bower; Denise Whitby
Journal:  Nat Rev Dis Primers       Date:  2019-01-31       Impact factor: 52.329

10.  Kaposi's Sarcoma Associated-Herpes Virus (KSHV) Seroprevalence in Pregnant Women in South Africa.

Authors:  Babatyi I Malope-Kgokong; Patrick Macphail; Georgina Mbisa; Edith Ratshikhopha; Mhairi Maskew; Lara Stein; Freddy Sitas; Denise Whitby
Journal:  Infect Agent Cancer       Date:  2010-08-31       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.